Lu B, Gong X, Wang Z-q, Ding Y, Wang C, Luo T-f, et al
First, let me preface this analysis by stating that I hold some Novo Nordisk A/S ( Analysts Disclosure: I/we have a beneficial long position in the shares of NVO either through stock ownership, options, or other derivatives
Summary GLP-1 receptor agonists slightly increase the risk of gallstones In particular, caution is needed with drugs that cause significant weight loss The mechanism is reduced gallbladder motility + rapid weight loss And what is important is that while there is a risk, the benefits often outweigh it is the point
See product label for suggested use
Understanding GLP-1 Injections GLP-1 (glucagon-like peptide-1) is a naturally occurring hormone that plays a crucial role in regulating appetite, insulin secretion, and glucose metabolism